EDSA Edesa Biotech, Inc.
XNAS
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
EDSA
—
—
Key stats
Related
About
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834) · industry map
- Exchange
- XNAS
- Market Cap
- $0.0B
- Employees
- 17
- List Date
- 2010-06-09
- CIK
- 0001540159
- Next Earnings
- 2026-12-11
- EPS Forecast
- ($0.58)
- Headquarters
- Markham
- Homepage
- https://www.edesabiotech.com
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | 33.95% | -30.65% | -25.00% | -4.91% | -0.03% | -22.00% | -8.11% |
| Feb | -10.97% | -16.82% | 1.42% | 1.72% | 12.31% | 78.86% | 11.09% |
| Mar | -5.10% | -15.86% | -34.38% | -12.85% | 18.45% | 129.39% | 13.27% |
| Apr | -0.72% | -24.49% | 12.26% | 4.79% | 0.43% | 229.28% | 36.93% |
| May | 3.29% | -3.74% | -19.47% | -2.75% | -17.65% | -58.95% | -16.54% |
| Jun | -11.41% | -19.90% | -10.88% | -6.75% | 2.01% | 21.52% | -4.24% |
| Jul | -6.20% | 12.50% | -1.80% | 20.73% | 10.84% | -34.45% | 0.27% |
| Aug | 15.32% | 9.94% | 0.83% | -14.02% | 8.41% | -9.46% | 1.84% |
| Sep | 20.59% | -48.82% | -24.49% | 3.49% | 5.51% | -11.92% | -9.27% |
| Oct | 19.13% | -6.36% | -31.94% | -28.88% | -27.63% | -35.91% | -18.60% |
| Nov | -25.56% | -10.46% | 3.24% | -23.73% | 0.57% | 2.05%* | -8.98% |
| Dec | -1.75% | 129.79% | 32.46% | -29.11% | -16.96% | -- | 22.89% |
| Total | 16.85% | -65.54% | -72.02% | -66.91% | -14.03% | 79.72% | -20.32% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $2.57
SMA 50: $3.50
SMA 200: $5.68
Current: $2.49
EMA 12: $2.46
EMA 26: $2.82
MACD: -0.3623 | Signal: 0.0233
BEARISH
ADX (14): 32.47
TREND
+DI: 41.52
−DI: 21.33
Momentum Oscillators
RSI (14): 39.84
NEUTRAL
Stoch %K: 14.37
Stoch %D: 8.41
Williams %R: -75.00
Volume & Volatility
BB Upper: $3.02
BB Lower: $2.12
NEUTRAL
OBV: 406,351,039
Vol SMA 20: 4,240,137
Vol ROC: 131272.38%
ATR: $0.37
True Range: $1.79
HV 20: 87.4%
HV 30: 105.6%
HV 60: 95.4%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-11-11T00:00:00 – 2026-11-09T00:00:00
AI Analysis
Written before EDSA’s Aug 14 earnings report, so it doesn’t reflect the results.
LLM Stock Analysis Report: Edesa Biotech, Inc. (EDSA)
Executive Summary
Overall Assessment: NEUTRAL (Confidence Level: 6/10)
Key Drivers:
- Strong technical momentum from recent breakout
- Positive news sentiment driven by emerging therapies in ARDS and vitiligo markets
- Low volatility regime suggests potential for further price appreciation
Primary Risks:
- Bearish MACD signal could lead to near-term pullback
- High RSI reading may indicate overbought conditions
- Uncertainty surrounding upcoming catalysts (e.g., earnings, FDA approvals)
2-3 Sentence Investment Thesis: EDSA is a moderately volatile stock with strong technical momentum, driven by positive news sentiment in emerging therapies. While the stock's recent breakout suggests potential for further price appreciation, caution is advised due to bearish MACD and high RSI readings.
Recent News Sentiment Impact: Positive headlines from ARDS and vitiligo markets have contributed to the stock's upward trend.
Technical Analysis
Trend Direction:
- Short-term: Bullish
- Medium-term: Bullish
- Long-term: Neutral (SMA 200 below current price)
Support/Resistance Levels:
- Key price levels: $5.24 (current), $5.72 (SMA 20), $6.42 (SMA 50)
- Resistance zones: $5.94 (EMA 26), $7.01 (Upper Bollinger Band)
Momentum Signals:
- RSI interpretation: Neutral (38.25) - not oversold or overbought
- MACD signal: Bearish (crossover below signal line)
- Bollinger Bands position: Mean reversion (price near middle band)
Volume Analysis:
- Volume trend: Weakly up-trending
- Institutional interest: Average volume suggests moderate institutional participation
News & Sentiment Analysis
Recent Headlines Summary:
- Positive news headlines from ARDS and vitiligo markets drive sentiment
- Neutral headlines provide no significant impact on sentiment
Sentiment Assessment:
- Aggregate sentiment: Positive (4/5)
Catalyst Identification:
- No upcoming earnings or FDA approvals
- Ongoing clinical trials in ARDS and vitiligo markets may drive future news sentiment
Market Narrative: Positive news sentiment aligns with technical momentum, suggesting a potential uptrend.
Risk & Volatility Assessment
Risk Metrics:
- Beta: -0.70 (vs SPY) - stock moves opposite to market
- Alpha: 2.54 - relatively high alpha suggests stock can outperform market
- Correlation: -0.05 - weak correlation with broader market
Volatility Regime:
- Current volatility: Low (1.93)
- Historical volatility: Moderate to high (HV20 72.3%, HV30 73.5%, HV60 146.0%)
Options Market Signals: No options data available.
Downside Protection:
- Support levels: $4.43 (Lower Bollinger Band), $4.98 (SMA 200)
- Risk management considerations: Stop-loss at $5.24, position sizing based on volatility
Market Context & Positioning
Sector Performance:
- Relative strength vs sector/market: Neutral
Institutional Activity:
- Volume patterns suggesting institutional interest: Moderate to high volume suggests some institutional participation
Correlation Analysis: Weak correlation with broader market (-0.05) - potential for independent price movement.
Relative Valuation:
- Position within trading range: Mid-range - not oversold or overbought.
Key Levels & Action Items
Critical Price Levels:
- Support/resistance to monitor: $5.24, $5.72, $6.42, $7.01
- Breakout/breakdown levels: $4.43 (Lower Bollinger Band), $4.98 (SMA 200)
Time-Sensitive Catalysts: No upcoming earnings or FDA approvals - focus on ongoing clinical trials.
Risk Management:
- Stop-loss at $5.24
- Position sizing based on volatility (1.93)
Note: This report is for informational purposes only and should not be considered a buy/sell recommendation. The provided analysis is based on publicly available data and may not reflect the author's personal opinion or views.
Generated
News
All EDSA news →
Earnings History
1 of 1 under expected move
Avg Expected Move
—
Avg Actual Move
5.61%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2026-08-14 | unknown | — | 5.61% | — | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
EDSA Options Activity & IV Rank
Loading options activity...
Spread Scanner
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Calendars: the long leg is valued at the short leg’s expiration (Black-Scholes at its current IV) across the range of prices the short leg’s IV implies, giving the best-case profit (R/R = that over the debit) and P(profit).
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Scanning bull put, bear call, iron condor and calendar spreads…
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
ATM — / Wing —
30 DTE / 10d
—
—
pts
EXTREME
ATM — / Wing —
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Loading the implied volatility surface…
Volatility Smile
Loading the implied volatility smile…
IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)
Beta Analysis
Risk Metrics
Beta: -0.3918
Alpha: 194.72%
Correlation: -0.0275
R-Squared: 0.1%
Stock Volatility: 195.7%
Market Volatility: 13.8%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
Negative beta - stock moves opposite to market
Negative beta - stock moves opposite to market
Beta & Alpha Over Time
EDSA Institutional Ownership (13F)
Filings for 2026-06-30 · 4 already for 2026-09-30Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
| # | Filer | Notional Value | % of Total | Period |
|---|
| # | Filer | Notional Value | % of Total | Period |
|---|
EDSA Insider Trading (Form 4)
Latest: 2026-11-05Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-11-05 | Pardeep Nijhawan | Chief Executive Officer | Award (A) | +18,677 | — | EDGAR | |
| 2026-10-29 | Pardeep Nijhawan | Chief Executive Officer | Award (A) | +27,602 | — | EDGAR | |
| 2026-10-06 | Pardeep Nijhawan | Chief Executive Officer | Award (A) | +6,893 | — | EDGAR | |
| 2026-09-01 | Pardeep Nijhawan | Chief Executive Officer | Award (A) | +5,714 | — | EDGAR | |
| 2026-08-04 | Pardeep Nijhawan | Chief Executive Officer | Award (A) | +5,324 | — | EDGAR | |
| 2026-07-02 | Pardeep Nijhawan | Chief Executive Officer | Award (A) | +3,378 | — | EDGAR | |
| 2026-06-16 | Pardeep Nijhawan | Chief Executive Officer | Award (A) | +153,550 | $5.21 | $800.0K | EDGAR |
| 2026-06-01 | Pardeep Nijhawan | Chief Executive Officer | Award (A) | +1,671 | — | EDGAR | |
| 2026-05-29 | Peter J. Weiler | Chief Financial Officer | Award (A) | +64,609 | — | EDGAR | |
| 2026-05-29 | Sean Arthur MacDonald | Director | Award (A) | +19,000 | — | EDGAR | |
| 2026-05-29 | Charles V Olson | Director | Award (A) | +19,000 | — | EDGAR | |
| 2026-05-29 | Da David Liu | Director | Award (A) | +19,000 | — | EDGAR | |
| 2026-05-29 | Patrick Marshall | Director | Award (A) | +19,000 | — | EDGAR | |
| 2026-05-29 | Joan Chypyha | Director | Award (A) | +19,000 | — | EDGAR | |
| 2026-05-29 | Carlo Sistilli | Director | Award (A) | +19,000 | — | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
EDSA Insider Holdings
9 insiders · @ $2.49
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Pardeep Nijhawan | Chief Executive Officer | 1,354,974 | $3.37M | $341.1K | 65 | 2026-11-05 |
| 2 | Michael J Brooks | President | 291,479 | $725.8K | $84.9K | 25 | 2026-05-29 |
| 3 | Peter J. Weiler | Chief Financial Officer | 129,609 | $322.7K | $0 | 2 | 2026-05-29 |
| 4 | Patrick Marshall | Director | 72,131 | $179.6K | $0 | 5 | 2026-05-29 |
| 5 | Carlo Sistilli | Director | 49,939 | $124.3K | $10.0K | 12 | 2026-05-29 |
| 6 | Sean Arthur MacDonald | Director | 41,054 | $102.2K | $0 | 10 | 2026-05-29 |
| 7 | Joan Chypyha | Director | 30,029 | $74.8K | $0 | 4 | 2026-05-29 |
| 8 | Charles V Olson | Director | 30,000 | $74.7K | $0 | 4 | 2026-05-29 |
| 9 | Da David Liu | Director | 24,501 | $61.0K | $0 | 2 | 2026-05-29 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
EDSA Board & Officers
As of SEC filings through Nov 5, 2026Directors 7
- Charles V Olson · since Dec 8, 2016
- Carlo Sistilli · since Jun 7, 2019
- Pardeep Nijhawan · since Jun 7, 2019
- Sean Arthur MacDonald · since Jun 7, 2019
- Joan Chypyha · since May 23, 2023
- Patrick Marshall · since May 23, 2023
- Da David Liu · since Feb 12, 2025
Officers 3
- Pardeep Nijhawan · Chief Executive Officer · since Jun 7, 2019
- Michael J Brooks · President · since Jun 7, 2019
- Peter J. Weiler · Chief Financial Officer · since May 1, 2025
10% owners 1
- Pardeep Nijhawan · since Jun 7, 2019
Changes in the last 10 years (34)
| May 1, 2025 | Peter J. Weiler became Chief Financial Officer |
| Feb 12, 2025 | Da David Liu became a director |
| Jul 15, 2023 | Stephen Lemieux became Chief Financial Officer |
| May 23, 2023 | The company announced the departure of Kathi Niffenegger as Chief Financial Officer in an SEC filing |
| May 23, 2023 | Patrick Marshall became a director |
| May 23, 2023 | Joan Chypyha became a director |
| Jan 11, 2023 | Velden Peter van der reported in an SEC filing no longer being a director |
| Jan 11, 2023 | Velden Peter van der reported in an SEC filing no longer being a 10% owner |
| Jan 11, 2023 | Lumira Capital Investment Management Inc. reported in an SEC filing no longer being a director |
| Jan 11, 2023 | Lumira Capital Investment Management Inc. reported in an SEC filing no longer being a 10% owner |
| Mar 28, 2022 | Jennifer M Chao became a director |
| May 28, 2020 | Pardeep Nijhawan Medicine Professional Corp first listed as a director in an SEC filing |
| May 28, 2020 | Pardeep Nijhawan Medicine Professional Corp first listed as Chief Executive Officer in an SEC filing |
| Jan 10, 2020 | Pardeep Nijhawan Medicine Professional Corp first on file as a 10% owner |
| Jan 10, 2020 | Lumira Capital Investment Management Inc. first listed as a director in an SEC filing |
| Sep 13, 2019 | Frank R. Oakes no longer listed as President & CEO in SEC filings |
| Jun 7, 2019 | Velden Peter van der became a director |
| Jun 7, 2019 | Velden Peter van der became a 10% owner |
| Jun 7, 2019 | Sean Arthur MacDonald became a director |
| Jun 7, 2019 | Paul William Pay became a director |
| Jun 7, 2019 | Pardeep Nijhawan became a director |
| Jun 7, 2019 | Pardeep Nijhawan became a 10% owner |
| Jun 7, 2019 | Pardeep Nijhawan became Chief Executive Officer |
| Jun 7, 2019 | Michael J Brooks became President |
| Jun 7, 2019 | Lumira Capital Investment Management Inc. became a 10% owner |
| Jun 7, 2019 | Lorin K Johnson became a director |
| Jun 7, 2019 | Carlo Sistilli became a director |
| Oct 12, 2018 | Daniel E. Morse reported in an SEC filing no longer being a director |
| Jan 23, 2018 | Deborah F. Aghib became a director |
| Mar 29, 2017 | Gregory T. Baxter no longer listed as a director in SEC filings |
| Mar 29, 2017 | Gregory T. Baxter first listed as EVP, Corporate Development in an SEC filing |
| Jan 12, 2017 | Frank R. Oakes listed as President & CEO (previously President, CEO & Director) in SEC filings |
| Dec 8, 2016 | Paul Chun became a director |
| Dec 8, 2016 | Charles V Olson became a director |
Not reported recently (12)
- Frank R. Oakes · Last reported as a director in an SEC filing dated May 30, 2024
- Pardeep Nijhawan Medicine Professional Corp · Last reported as a 10% owner in an SEC filing dated Mar 25, 2024
- Stephen Lemieux · Last reported as Chief Financial Officer in an SEC filing dated Aug 4, 2023
- Paul William Pay · Last reported as a director in an SEC filing dated May 18, 2022
- Lorin K Johnson · Last reported as a director in an SEC filing dated May 18, 2022
- Jennifer M Chao · Last reported as a director in an SEC filing dated May 18, 2022
- Tessie M Che · Last reported as a director in an SEC filing dated Mar 13, 2019
- David Louis Hill · Last reported as a director in an SEC filing dated Mar 13, 2019
- Mayank D. Sampat · Last reported as a director in an SEC filing dated Mar 13, 2019
- Paul Chun · Last reported as a director in an SEC filing dated Mar 13, 2019
- Deborah F. Aghib · Last reported as a director in an SEC filing dated Mar 13, 2019
- Gregory T. Baxter · Last reported as EVP, Corporate Development in an SEC filing dated Mar 14, 2018
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
Recent SEC Filings
Latest: 2026-10-23
Current reports — material events the company must disclose within 4 business days (earnings releases, M&A, executive changes, etc.).
| Filing Date | Event | Link |
|---|---|---|
| 2026-10-23 | Director or officer change | EDGAR |
| 2026-10-15 | Other events | EDGAR |
| 2026-08-20 | Material agreement · Other events | EDGAR |
| 2026-08-13 | Earnings results | EDGAR |
| 2026-06-11 | Material agreement · Unregistered share sale · Regulation FD disclosure | EDGAR |
| 2026-06-05 | Other events | EDGAR |
Annual report — audited financial statements, MD&A, risk factors. Filed 60–90 days after fiscal year-end.
| Filing Date | Accession | Link |
|---|
Quarterly report — unaudited financials and MD&A. Filed 40–45 days after each of the first three fiscal quarters.
| Filing Date | Accession | Link |
|---|---|---|
| 2026-08-13 | 0001171843-26-005502 | EDGAR |
ETF Holders
1 ETF hold EDSA
1 shown · $344.54K total exposure
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | VXF Vanguard Extended Market ETF | Vanguard | 0.00% | $344,542 | — | 2026-09-30 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
EDSA vs Peers
Related companies, largest first| Company | Market cap | P/E | Revenue growth | YTD | IV rank |
|---|---|---|---|---|---|
| LLY Eli Lilly & Co. | $1.21T | 45.8 | +45.5% | +30.7% | 27 |
| JNJ Johnson & Johnson | $664.9B | 42.8 | +7.8% | +36.1% | 54 |
| ABBV ABBVIE INC. | $514.9B | 50.5 | +10.7% | +27.9% | 30 |
| MRK Merck & Co., Inc. | $361.7B | 153.4 | +4.9% | +39.7% | 44 |
| NVS Novartis AG | $307.0B | — | — | +18.2% | 36 |
| AZN AstraZeneca PLC | $289.1B | — | — | +106.8% | 0 |
| ABT Abbott Laboratories | $190.4B | 40.9 | +10.0% | −11.0% | 20 |
| NVO Novo-Nordisk A/S | $177.7B | — | — | −21.0% | 15 |
| EDSA Edesa Biotech, Inc. Common Shares | $21M | — | — | +66.0% | — |
| Peer median | $334.4B | 45.8 | +10.0% | +29.3% | 28 |
P/E uses the latest reported trailing-12-month diluted EPS; "—" means no positive earnings or no data.